The improvement effect of liver dysfanction and inhibitory effect of fibrosis marker by sitagliptin or repaglinide treatment for fatty liver(liver dysfunction) patients with type2 diabetes mellitus.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Sitagliptin (Primary) ; Repaglinide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 07 Jun 2016 Planned End Date changed from 31 Dec 2014 to 31 Dec 2016.
- 10 Dec 2014 New trial record